Drugs / Adrenocorticotropic hormone (ACTH)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT02446886 | Jun 2016 → Mar 2020 | multiple sclerosis | Weill Medical College of Cornell University | Terminated | Met primary Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adrenocorticotropic hormone (ACTH) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02446886 ↗ |
| Modality | Peptide | “Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides” NCT02446886 ↗ |
| Route | Subcutaneous | “a subcutaneous daily dose” NCT02446886 ↗ |